Home > Search Results

Results: 21 to 40 of 54

The use of the monoclonal antibody rituximab in patients with relapsing remitting multiple sclerosis (RRMS)

This is an update of the Cochrane review "Rituximab for relapsing‐remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Sufficient data were available from 22 studies on the following drugs: cladribine (Movectro), glatiramer acetate (Copaxone), interferon beta‐1b (Betaferon), interferon beta‐1a (Rebif; Avonex), and teriflunomide (Aubagio).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

Decisional Dilemmas in Discontinuing Prolonged Disease-Modifying Treatment for Multiple Sclerosis [Internet]

We conducted a systematic review to examine the long-term consequences of discontinuing disease-modifying treatment (DMT) for multiple sclerosis (MS) by examining the long-term benefits and harms, and the reasons for discontinuing treatment. We also examined the evidence for people's values, beliefs, and preferences regarding discontinuing DMT.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: April 2015
Show search results within this document

Outcomes of Sipuleucel-T Therapy [Internet]

Sipuleucel-T (Provenge®, Dendreon Corporation) is a recently approved treatment for asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. This technology assessment is a systematic review of studies of the clinical outcomes of sipuleucel-T treatment. The review is organized by three Key Questions. These questions address the following: 1) the outcomes of sipuleucel-T for patients meeting the U.S. Food and Drug Administration (FDA)-labeled indications; 2) the outcomes of sipuleucel-T for patients not meeting the FDA-labeled indication (“off-label use”); and 3) adverse effects of sipuleucel-T treatment. Key Questions 1 and 2 also include subquestions to address possible interactions and mediators of the outcomes of sipuleucel-T treatment.

Technology Assessment Report - Agency for Healthcare Research and Quality (US).

Version: February 10, 2011
Show search results within this document

Adult Acute Myeloid Leukemia Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: January 20, 2017

Teriflunomide (Aubagio) (14 mg Film-coated Tablet): Teriflunomide is Indicated as Monotherapy for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis to Reduce the Frequency of Clinical Exacerbations and to Delay the Accumulation of Physical Disability [Internet]

The objective of this systematic review is to examine the beneficial and harmful effects of teriflunomide for the treatment of relapsing-remitting form of MS (RRMS).

Common Drug Review - Canadian Agency for Drugs and Technologies in Health.

Version: October 2014
Show search results within this document

Teriflunomide modifies the disease course in people with multiple sclerosis

Teriflunomide was first used in rheumatoid arthritis, and is known to possess both anti‐proliferative (inhibiting cell growth) and anti‐inflammatory (counteracting a local response to cellular injury) actions. In 2012, its use was approved for these characteristics by the US Food and Drug Administration for people with relapsing (with recurrent exacerbations of neurological symptoms) forms of multiple sclerosis (MS) and in 2013 also by the European Medicines Agency.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet]

We compared the effectiveness and harms of fingolimod (Gilenya™) to other disease-modifying drugs in the treatment of multiple sclerosis.

Drug Class Reviews - Oregon Health & Science University.

Version: February 2011
Show search results within this document

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood acute lymphoblastic leukemia.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 14, 2017

Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: May 12, 2017

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 4, 2017

Non-Hodgkin's Lymphoma: Diagnosis and Management

Non-Hodgkin's lymphoma is the sixth most common cancer in the UK. There are many different subtypes of the disease, with markedly different clinical courses and requirements for therapy. Diagnosing non-Hodgkin's lymphoma and the precise subtype is challenging, and optimising the diagnostic process is central to improved management. Significant improvements in our understanding of the biology of non-Hodgkin's lymphoma have contributed to improved diagnosis and also allowed for more targeted therapies.

NICE Guideline - National Guideline Alliance (UK).

Version: July 2016
Show search results within this document

Addendum to Haematological Cancers: Improving Outcomes (Update)

Different levels of service are needed to manage haematological cancers, depending on the particular cancer in question. Because of the increased complexity of care and changes in the levels of care from those specified in the 2003 NICE cancer service guidance on improving outcomes in haematological cancers, an update was needed.

NICE Guideline - National Collaborating Centre for Cancer (UK).

Version: May 2016
Show search results within this document

Optimizing Health System Use of Medical Isotopes and Other Imaging Modalities [Internet]

The purpose of this project was to provide national guidance on the optimal use of 99mTc during a situation of reduced supply. To accomplish this, our objective at CADTH was:

Optimal Use Report - Canadian Agency for Drugs and Technologies in Health.

Version: 2012
Show search results within this document

Prostate Cancer Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of prostate cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: March 31, 2017

Prostate Cancer: Diagnosis and Treatment

The original Prostate Cancer: Diagnosis and Treatment Guideline published in 2008 was the first clinical guideline produced by the National Collaborating Centre for Cancer (NCC-C); accordingly this is now the first NCC-C clinical guideline to be reviewed and updated. Many areas of the original guideline are unchanged as there is little or no new evidence; other aspects have been completely rewritten. As ever there are still many topics where the research evidence is incomplete or conflicting, and so the Guideline Development Group (GDG) have been required to reach a consensus using the evidence available to them in several areas. In places where it was clear that further work needed to be done, new research recommendations have been made which we hope will be used as the basis for future research work.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: January 2014
Show search results within this document

Cardiopulmonary Syndromes (PDQ®): Health Professional Version

Expert-reviewed information summary about common conditions that produce chest symptoms. The cardiopulmonary syndromes addressed in this summary are cancer-related dyspnea, malignant pleural effusion, pericardial effusion, and superior vena cava syndrome.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 24, 2016

Minimal Modeling Approaches to Value of Information Analysis for Health Research [Internet]

Value of information (VOI) techniques can provide estimates of the expected benefits from clinical research studies. These VOI estimates can inform decisions about the design and priority of those studies. Most VOI studies use decision analytic models to characterize the uncertainty of the effects of interventions on health outcomes. For some potential applications of VOI, the complexity of constructing such models poses barriers to practical application of VOI. However, because some clinical studies can directly characterize uncertainty in health outcomes, it may sometimes be possible to perform VOI analysis with only minimal modeling. This paper (1) develops a framework to define and classify minimal modeling approaches to VOI; (2) reviews existing VOI studies that apply minimal modeling approaches; and (3) illustrates and discusses the application of the minimal modeling to two new clinical applications to which the approach appears well suited because clinical trials with comprehensive outcomes provide preliminary estimates of the uncertainty in outcomes. We conclude that minimal modeling approaches to VOI can be readily applied to in some instances to develop estimates of the expected benefits of clinical research.

Methods Future Research Needs Reports - Agency for Healthcare Research and Quality (US).

Version: June 2011
Show search results within this document

Advanced Breast Cancer: Diagnosis and Treatment

Breast cancer is the most common cancer for women in England and Wales, with about 37,000 new cases diagnosed and 11,000 deaths recorded in England and Wales each year. In men breast cancer is rare, with about 270 cases diagnosed, and 70 deaths in England and Wales each year. Of these new cases in women and men, around 10% are diagnosed in the advanced stages, when the tumour has spread significantly within the breast or to other organs of the body. In addition, there is a significant number of women who have been previously treated with curative intent who subsequently develop either a local recurrence or metastases. Over recent years there have been important developments in the investigation and management of these patients including new chemotherapy, and biological and hormonal agents. There is some evidence of practice variation across the country and of patchy availability of certain treatments and procedures. A clinical guideline will help to address these issues and offer guidance on best practice.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: February 2009
Show search results within this document

Treatment-Related Nausea and Vomiting (PDQ®): Health Professional Version

Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: May 10, 2017

Systematic Reviews in PubMed

See all (112)...

Systematic Review Methods in PubMed

See all (2)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...